Antiretroviral therapy transforms HIV from a fatal diagnosis into a manageable chronic condition by suppressing the virus to undetectable levels in the blood, allowing the immune system to rebuild. When taken consistently, modern regimens drive the amount of virus in a person’s blood below 50 copies per milliliter, a threshold at which transmission to sexual partners does not occur. But ART does not eliminate HIV from the body entirely, and the interplay between what it can and cannot do shapes nearly every conversation about treatment, prevention, and the long pursuit of a cure.
How the Drugs Block HIV
HIV needs to complete several steps to reproduce: it has to latch onto and enter a human immune cell, convert its genetic material from RNA into DNA, stitch that DNA into the cell’s own genome, and then hijack the cell’s machinery to churn out new virus particles. Antiretroviral drugs are designed to interrupt specific steps in that cycle, and modern treatment combines drugs from different classes so the virus faces multiple roadblocks at once.
The oldest and still most widely used class is the nucleoside reverse transcriptase inhibitors, or NRTIs. These drugs mimic the building blocks the virus uses to construct its DNA copy. When HIV’s reverse transcriptase enzyme grabs one of these decoys and plugs it into the growing DNA chain, the chain can no longer be extended, and viral replication stalls.1PubMed. Perspectives on the molecular mechanism of inhibition and toxicity of nucleoside analogs that target HIV-1 reverse transcriptase A newer experimental compound, EFdA, works through a slightly different trick: instead of lacking the chemical handle needed to add the next building block, it physically jams the enzyme’s machinery so the DNA strand cannot slide forward into position for the next addition.2Journal of Biological Chemistry. Translocation-defective Reverse Transcriptase Inhibitors
Integrase strand transfer inhibitors, or INSTIs, target a later step. After the virus has made its DNA copy, an enzyme called integrase splices that DNA into the human cell’s chromosomes. INSTIs block this splicing step, preventing the virus from permanently embedding itself in the host genome.3PubMed Central. Structural Biology of HIV Integrase Strand Transfer Inhibitors Entry inhibitors take yet another approach by stopping the virus from getting inside the cell in the first place, either by blocking the receptor the virus grabs onto or by interfering with the molecular machinery the virus uses to fuse with the cell membrane.4Oxford Academic (Journal of Antimicrobial Chemotherapy). HIV entry inhibitors: mechanisms of action and resistance pathways
By combining two or three drugs that hit different targets, treatment makes it extraordinarily difficult for the virus to develop resistance to everything at once. This principle of combination therapy is the foundation of all modern ART regimens.
What Happens When Treatment Starts
Once someone begins ART, the amount of virus circulating in their blood drops fast, but not in a single smooth slide. The decline happens in two distinct phases. The first phase is steep and quick: the cells producing most of the virus in the blood have very short lifespans, and as ART prevents new cells from getting infected, the viral load plummets within days.5PubMed Central. Complex decay dynamics of HIV virions, intact and defective proviruses, and 2LTR circles following initiation of antiretroviral therapy The second phase is slower, with a half-life of about two weeks, reflecting a different population of infected cells that turn over more gradually. Within weeks to a few months, most people on effective ART reach an undetectable viral load.
Immune recovery follows a different timeline. CD4 cells, the immune cells HIV preferentially destroys, begin to climb back, but the pace depends heavily on how quickly the virus is suppressed. Research tracking patients over several years found that how fast the viral load drops in the first year of treatment strongly predicted CD4 gains during that early window, while the cumulative amount of virus a person was exposed to over time mattered more for longer-term immune recovery.6PubMed Central. Cumulative Viral Load and Virologic Decay Patterns after Antiretroviral Therapy in HIV-Infected Subjects Influence CD4 Recovery and AIDS The practical takeaway is straightforward: starting treatment earlier, before the immune system has been deeply damaged, gives the best chance of full immune recovery.
Why ART Cannot Cure HIV
Even years of perfectly suppressive treatment leaves HIV hiding in the body. Very early in infection, HIV integrates its DNA into a small number of long-lived resting immune cells. These cells are not actively producing virus, so the immune system does not recognize them as infected, and ART has nothing to block because the virus is not replicating. This pool of silently infected cells is called the latent reservoir, and it is the single biggest obstacle to curing HIV.7PubMed Central. The reservoir of latent HIV
The reservoir is stubbornly durable. Researchers have tried to measure how readily the dormant virus can be coaxed out by stimulating these resting cells in the lab. In one study, repeated rounds of stimulation managed to reactivate only about 1.7% of intact viral copies across all the different subtypes of resting CD4 cells examined.8PubMed Central. Different human resting memory CD4(+) T cell subsets show similar low inducibility of latent HIV-1 proviruses That number underscores how deeply entrenched the virus becomes: even aggressive laboratory stimulation barely dents the reservoir. If someone stops ART, the virus rebounds from these hidden cells within weeks, which is why lifelong treatment remains necessary.
Sanctuary Sites and the Brain
The latent reservoir is not the only place the virus hides. Certain areas of the body are harder for drugs to reach, and the brain is the most discussed of these so-called sanctuary sites. The blood-brain barrier, a tightly sealed network of cells lining the brain’s blood vessels, protects the central nervous system from toxins and pathogens but also restricts drug delivery. While ART drugs do cross into the brain, their concentrations there are far lower than in the bloodstream. Abacavir, for example, reaches only a fraction of its blood plasma level in cerebrospinal fluid, and efavirenz accumulates in the brain at concentrations roughly a hundred-fold lower than in the blood.9PubMed Central. The Paradox of HIV Blood-Brain Barrier Penetrance and Antiretroviral Drug Delivery Deficiencies
This matters clinically because HIV can replicate at low levels in the brain even when the blood viral load is fully suppressed. Over time, this can contribute to a condition known as HIV-associated neurocognitive disorder, which can range from subtle difficulties with concentration and memory to more serious impairment.10PubMed Central. HIV-Associated Neurocognitive Disorder (HAND) and the Prospect of Brain-Penetrating Protease Inhibitors for Antiretroviral Treatment Developing drugs that penetrate the brain more effectively is an active area of research, both for better long-term neurological outcomes and for any eventual cure strategy that would need to reach virus throughout the body.
Long-Acting Injectables and Newer Drug Classes
For decades, ART meant swallowing pills every day. That has changed. The first long-acting injectable regimen, a combination of cabotegravir and rilpivirine given as two intramuscular injections every one or two months, has become an option for people who are already virally suppressed. A pivotal trial found that at 48 weeks, roughly 93% of participants on the long-acting injections maintained viral suppression, which was comparable to the 96% rate in the daily-pill group.11PubMed. Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression The most common side effect was injection-site pain, reported by about three-quarters of recipients, though it was mild or moderate in most cases and only 1% stopped treatment because of it.
Real-world experience with this injectable regimen in people who have had trouble sticking to daily pills has been encouraging. Virologic outcomes remain strong, although the rate of treatment failure is somewhat higher than in the tightly controlled clinical trials that enrolled only people already stably suppressed.12PubMed Central. Use of long-acting injectable cabotegravir/rilpivirine in people with HIV and adherence challenges For those who do experience failure on the injectable combination, a newer long-acting drug called lenacapavir offers a fallback.
Lenacapavir is a first-in-class capsid inhibitor, meaning it targets the protein shell that surrounds HIV’s genetic material and plays roles at multiple stages of the viral life cycle. Because its mechanism is entirely distinct from older drug classes, it works against virus that has accumulated resistance to other treatments. In a trial of people with multidrug-resistant HIV, about 83% achieved an undetectable viral load by week 52 when lenacapavir was added to their optimized regimen.13The Lancet HIV. Efficacy and safety of lenacapavir in adults with multidrug-resistant HIV-1: week 52 results of a multicentre, open-label, phase 2/3 trial Lenacapavir is dosed as a subcutaneous injection every six months, which could eventually simplify treatment to just two clinic visits per year for some patients.
Drug Resistance and the Genetic Barrier
HIV mutates rapidly, and any drug used alone will quickly face resistant variants. The key protection against resistance in modern ART is the concept of a genetic barrier: how many mutations the virus would need to accumulate before a drug stops working. Some drugs have a low barrier, meaning a single mutation is enough, while others require the virus to pile up several changes simultaneously, which is far less likely.
Dolutegravir, one of the most widely prescribed integrase inhibitors, has an unusually high genetic barrier. Across pivotal trials in people starting treatment for the first time, none of the more than 1,100 participants on dolutegravir-based regimens developed resistance mutations to either the integrase inhibitor or the reverse transcriptase inhibitors in their regimen.14Reviews in Antiviral Therapy. Genetic Barrier to Resistance for Dolutegravir This robustness is a major reason dolutegravir-based regimens have become the default first-line treatment recommended by the World Health Organization in most settings. It also provides a safety margin for people whose adherence is imperfect: missing occasional doses is less likely to breed resistance than it would be with drugs that have a lower genetic barrier.
Prevention Beyond Treatment
ART’s impact extends well beyond the individual taking it. The principle of Undetectable = Untransmittable, or U=U, has been validated by large prospective studies. The PARTNER2 study followed gay male couples where one partner was HIV-positive and on suppressive ART while the other was HIV-negative. Over thousands of couple-years of follow-up with no condom use, there were zero linked HIV transmissions when the positive partner’s viral load was below 200 copies per milliliter.15The Lancet. Risk of sexual transmission of HIV in serodifferent couples using suppressive antiretroviral therapy (PARTNER2) The upper statistical bound on the transmission rate worked out to roughly one event per 435 couple-years of condomless sex, and even that is a theoretical ceiling, not an observed event.
ART drugs are also used preventively by HIV-negative people. Pre-exposure prophylaxis, or PrEP, uses the same antiretroviral medications taken before potential exposure to block the virus from establishing infection. Daily oral PrEP with tenofovir-based combinations reduces the risk of acquiring HIV by over 90% when taken consistently.16JAMA. HIV Preexposure Prophylaxis: A Review A newer formulation using tenofovir alafenamide (TAF) instead of the older tenofovir disoproxil fumarate (TDF) was shown to be equally effective at preventing HIV while offering a somewhat better kidney and bone safety profile over 96 weeks of follow-up.17The Lancet HIV. Once-daily emtricitabine and tenofovir alafenamide versus emtricitabine and tenofovir disoproxil fumarate for pre-exposure prophylaxis of HIV (DISCOVER) Long-acting injectable cabotegravir, given every two months, has also been approved for PrEP, and lenacapavir is being studied as a twice-yearly injection for prevention.
Side Effects and the Weight Gain Question
Modern ART is vastly better tolerated than the early regimens, which were notorious for causing severe fat redistribution, nausea, and organ damage. But today’s preferred drugs come with their own side-effect profile, and weight gain has emerged as the most visible concern. Regimens that combine an integrase inhibitor with TAF are associated with the most weight increase. At two years, people starting INSTI-based regimens gained an average of about 5 kilograms, compared to about 3 kilograms for those on non-nucleoside-based regimens.18PubMed Central. Weight Gain on Contemporary Integrase Strand Transfer Inhibitors and Tenofovir Alafenamide in Persons With HIV Starting Antiretroviral Therapy in the United States and Canada The effect is not evenly distributed: Black women on bictegravir or dolutegravir with TAF experienced the highest average gain, around 10 kilograms at two years.
Part of the TAF-associated weight gain may reflect the removal of a weight-suppressing effect of the older TDF rather than TAF actively promoting fat accumulation, a distinction that researchers are still working to untangle.19PubMed. Impact of Integrase inhibitors and tenofovir alafenamide on weight gain in people with HIV Switching to an INSTI-based regimen has also been linked to a trend toward modestly increased LDL cholesterol, though changes in total cholesterol, blood sugar, and HDL were not significant in one study tracking metabolic markers after the switch.20PubMed Central. Weight gain and metabolic effects in persons with HIV who switch to ART regimens containing integrase inhibitors or tenofovir alafenamide
Kidney toxicity remains a concern with certain drugs, particularly tenofovir (the older TDF formulation) and the protease inhibitor indinavir, which is now rarely used. TDF has been associated with damage to the kidney’s proximal tubules and, in some cases, acute kidney injury.21PubMed. Antiretroviral medications: adverse effects on the kidney The shift toward TAF-based regimens was partly motivated by its gentler profile on the kidneys and bones, though the tradeoff appears to be the increased weight gain discussed above.
Treating HIV Alongside Tuberculosis
Tuberculosis is the leading cause of death among people living with HIV worldwide, and managing the two infections together is one of the trickiest problems in global health. The central challenge is pharmacological: rifampin, the backbone drug for TB treatment, powerfully revs up liver enzymes that metabolize many antiretroviral drugs, especially protease inhibitors and some non-nucleoside agents. The result is that ART drug levels can drop enough to allow the virus to replicate and develop resistance.22The Journal of Infectious Diseases. Complications of Antiretroviral Therapy in Patients with Tuberculosis: Drug Interactions, Toxicity, and Immune Reconstitution Inflammatory Syndrome
On top of the drug interaction problem, starting ART in someone being treated for TB can trigger a flare-up called immune reconstitution inflammatory syndrome, or IRIS. As the recovering immune system suddenly recognizes TB bacteria it had been too weakened to fight, it can mount an excessive inflammatory response, causing fever, swollen lymph nodes, and worsening of TB symptoms. Prednisone has shown benefit for managing TB-IRIS, and the timing of when to start ART relative to TB treatment is a careful balancing act: starting too early increases the IRIS risk, while waiting too long leaves the person vulnerable to other opportunistic infections.23PubMed Central. Management of individuals requiring ART and TB treatment
Children and Pregnant Women
ART given during pregnancy, labor, and breastfeeding has dramatically reduced mother-to-child transmission of HIV, cutting what was once a roughly 25-40% transmission rate to below 2% in settings where treatment is reliably available.24PubMed Central. Antiretroviral drug regimens to prevent mother-to-child transmission of HIV: a review of scientific, program, and policy advances for sub-Saharan Africa However, treating infants and young children who do acquire HIV presents unique difficulties. Many antiretroviral drugs were developed and tested primarily in adults, and liquid formulations suitable for infants are limited in number, often taste bad, and may require refrigeration that is hard to guarantee in resource-limited settings.25PubMed. Pediatric Antiretroviral Therapy
Beyond palatability, children metabolize drugs differently at different ages, and dosing data from adult studies do not translate reliably to newborns, toddlers, or adolescents. Pediatric fixed-dose combination tablets exist but are fewer in number than adult versions, and crushing adult tablets to approximate a child’s dose introduces uncertainty about how much drug the child actually receives.26PubMed. Antiretroviral drugs in pediatric HIV-infected patients: pharmacokinetic and practical challenges The development of palatable dispersible tablets and long-acting formulations for children is a priority, but progress has been slow relative to the pace of adult drug development.
Aging With HIV and the Polypharmacy Problem
Thanks to ART’s effectiveness, the average age of people living with HIV is climbing steadily. In high-income countries, roughly half the HIV-positive population is now over 50. Living longer also means accumulating the health problems of aging: heart disease, high blood pressure, diabetes, kidney disease, and cancer. Each of these conditions brings its own medications, and the resulting pile-up of prescriptions creates a tangle of potential drug interactions.
In one study, polypharmacy, defined as taking five or more non-ART medications, was present in 44% of people with HIV aged 65 and older, compared to just 12% of younger adults with HIV.27PubMed Central. Polypharmacy, Drug–Drug Interactions, and Inappropriate Drugs: New Challenges in the Aging Population With HIV Cardiovascular drugs were the most common non-ART medications in the older group, appearing in nearly three-quarters of prescriptions. About a third of the older group was also receiving at least one potentially inappropriate medication, most often sleeping pills or anti-anxiety drugs that carry added risks for older adults. Antiretrovirals interact with many of these medications through shared liver enzyme pathways and drug transporters, potentially boosting or reducing levels of either the ART drugs or the co-medications.28PubMed Central. An update on drug-drug interactions in older adults living with human immunodeficiency virus (HIV)
This makes medication review by a pharmacist or HIV specialist increasingly important as people with HIV age. Simplifying ART regimens to single-tablet or long-acting injectable options can reduce the interaction surface, but it does not eliminate the need to check every new prescription against the antiretroviral backbone.
The Search for a Cure
The most widely discussed cure strategy is known as “shock and kill.” The idea is conceptually simple: use a chemical agent to wake up the dormant virus hiding in resting immune cells (the “shock”), then rely on the immune system or the virus itself to destroy those newly activated cells (the “kill”).29PubMed Central. Getting the “Kill” into “Shock and Kill”: Strategies to Eliminate Latent HIV Several compounds called latency-reversing agents have been tested in clinical trials and can indeed wake up some of the sleeping virus. The problem is the kill half: simply flipping the virus back on has not been enough to cause the infected cells to die. Some latency-reversing agents may actually promote cell survival, working against the very goal they are supposed to serve.
Newer research is exploring combinations that add a deliberate cell-killing component, such as drugs that trigger programmed cell death, borrowed from cancer therapy, or enhanced immune cells like natural killer cells that can hunt down reactivated infected cells. Mathematical modeling suggests that a three-pronged approach combining ART, latency-reversing agents, and natural killer cells could potentially clear the reservoir faster than any two-pronged combination.30PubMed. Modeling the effects of a Shock-and-Kill Treatment for HIV: Latency-Reversing Agents and Natural Killer Cells These strategies remain in early stages, and the brain’s role as a viral sanctuary adds another layer of difficulty, since any cure approach must also reach virus that has established itself behind the blood-brain barrier.31PubMed Central. Shock and kill within the CNS: A promising HIV eradication approach?
Generic Drugs and Global Access
The story of ART is inseparable from the story of who can actually get it. In the early 2000s, antiretroviral treatment cost over $10,000 per person per year in wealthy countries, putting it out of reach for the vast majority of people living with HIV, most of whom were in sub-Saharan Africa. The development of generic fixed-dose combinations, which package multiple drugs into a single pill, was pivotal in driving costs down to a few hundred dollars per year. However, generic versions of older regimens became available much sooner than generics of newer, better-tolerated drugs. By the mid-2000s, 24 generic fixed-dose combinations had received international quality approval for older regimens but only four for newer ones.32PubMed Central. Intervening in global markets to improve access to HIV/AIDS treatment: an analysis of international policies and the dynamics of global antiretroviral medicines markets The timeline for regulatory approvals also varied: generic combinations were available to recipients of the Global Fund as early as 2004 but only reached PEPFAR-funded programs after FDA approval in 2006.
Access has improved enormously since then. UNAIDS estimates that over 30 million people were on ART by the end of 2023, compared to fewer than a million in 2000. But gaps persist, particularly in reaching children, adolescents, and key populations in countries with restrictive laws around HIV testing and treatment. The arrival of long-acting injectables and six-monthly drugs like lenacapavir raises new access questions: these products require cold-chain storage and clinical visits for injections, which could either improve coverage by reducing the adherence burden or widen inequalities if the infrastructure to deliver them is not built out in lower-resource settings.